Company profile
XENCOR INC
NASDAQ:XNCRBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PLAMOTAMAB | phase2 | — | 3 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (29)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07284797 | phase1 | recruiting | 2026-02-24 | 2028-10-01 | Xencor, Inc. | A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases |
| NCT07230353 | phase1 | recruiting | 2025-10-21 | 2028-06-01 | Xencor, Inc. | A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid Arthritis |
| NCT05032040 | phase2 | active_not_recruiting | 2022-07-21 | 2025-10-15 | Xencor, Inc. | A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies |
| NCT03411915 | phase1 | completed | 2018-01-22 | 2021-10-26 | Xencor, Inc. | A Study of XmAb®18087 in Subjects With NET and GIST |
| NCT03517488 | phase1 | completed | 2018-07-10 | 2022-06-01 | Xencor, Inc. | A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors |
FDA applications (0)
No records yet.